Merus NV: Positive Developments and Analyst Upgrades

Merus NV, a clinical-stage immuno-oncology company listed on the Frankfurt Stock Exchange, has recently experienced significant positive developments. The company, headquartered in Utrecht, Netherlands, focuses on developing bispecific antibody therapeutics aimed at treating and curing cancer patients. Here’s a summary of the latest financial news and developments concerning Merus NV:

Analyst Upgrades and Price Target Increases

  • BofA and BMO Analyst Actions: On May 25, 2025, both Bank of America (BofA) and BMO Capital Markets maintained a “Buy” and “Outperform” rating on Merus NV, respectively. BofA lifted its price target, while BMO raised its price target from $96.00 to $110.00 following positive Phase 2 data. These actions reflect growing confidence in Merus’s potential.

  • Stock Performance: Following these analyst upgrades, Merus NV’s shares experienced a significant gap up. The stock, which had closed at $41.60, opened at $50.20 on May 25, 2025, and last traded at $53.82 with a volume of 2,516,414 shares.

Clinical Trial Success

  • Positive Phase 2 Data: Merus NV reported robust efficacy and durability in the first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) using Petosemtamab in combination with Pembrolizumab. The interim results showed a 63% response rate among 24 evaluable patients and a 79% overall survival rate at 12 months, with a median progression-free survival of 9 months.

  • Conference Announcement: A conference call was scheduled for Thursday, May 22, 2025, at 17:30 Eastern Time to discuss these promising results further.

Company Overview

  • Sector and Industry: Merus NV operates in the Health Care sector, specifically within the Biotechnology industry, focusing on innovative multispecific antibodies.

  • Financial Metrics: As of May 21, 2025, Merus NV’s close price was €37.4, with a market capitalization of €2.65 billion. The company’s 52-week high was €55.5, and its low was €29.4. The price-to-earnings ratio stands at -10.09, reflecting the company’s current stage of development.

These developments highlight Merus NV’s potential in the immuno-oncology space, driven by promising clinical trial results and strong analyst support. For more information, visit Merus NV’s website .